Mass High Tech

Biogen Idec Q1 revenues up 7 percent
Mass High Tech
... has announced that its first-quarter revenues for the three months ending on March 31 were $1.3 billion, up 7 percent from the same time a year before, due largely to increased sales of the drugs Tysabri (natalizumab) and Rituxan (rituximab).
Biogen Idec Increases Revenue 7% to $1.3 Billion in the First QuarterMarketWatch (press release)
Biogen Idec's CEO Discusses Q1 2012 Results - Earnings Call TranscriptSeeking Alpha

all 38 news articles »